Cargando…
Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel
BACKGROUND: Fluralaner (Bravecto™; Merck/MSD Animal Health) is a novel systemic ectoparasiticide for dogs providing long-acting flea and tick control after a single oral dose. Milbemycin oxime and praziquantel are routinely used to control Dirofilaria immitis and intestinal worm infections in dogs....
Autores principales: | Walther, Feli M, Fisara, Petr, Allan, Mark J, Roepke, Rainer KA, Nuernberger, Martin C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198702/ https://www.ncbi.nlm.nih.gov/pubmed/25315498 http://dx.doi.org/10.1186/s13071-014-0481-y |
Ejemplares similares
-
Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin)
por: Walther, Feli M, et al.
Publicado: (2014) -
Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats
por: Walther, Feli M., et al.
Publicado: (2018) -
Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs
por: Walther, Feli M., et al.
Publicado: (2015) -
Safety of concurrent treatment of cats with fluralaner and emodepsid–praziquantel
por: Walther, Feli M., et al.
Publicado: (2016) -
Safety of fluralaner chewable tablets (Bravecto(TM)), a novel systemic antiparasitic drug, in dogs after oral administration
por: Walther, Feli M, et al.
Publicado: (2014)